A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

This study tests a new combination treatment — the experimental drug GH21 combined with osimertinib (a standard targeted therapy) — in people with advanced non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation and has stopped responding to previous targeted therapy. **You may be eligible if...** - You are 18 years or older - You have advanced NSCLC confirmed to have an EGFR mutation by biopsy or cytology - Your cancer has progressed after treatment with at least one third-generation EGFR-targeted drug (like osimertinib) - Your cancer has at least one measurable tumor on imaging **You may NOT be eligible if...** - You have not yet tried any EGFR-targeted therapy - Your cancer does not have an EGFR mutation - Your organ function or performance status does not meet the study requirements - You cannot consent or comply with the study procedures Talk to your doctor to see if this trial is right for you.